Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China
Author:
Funder
Health and Family Planning Commission of Hunan Province
Publisher
Elsevier BV
Subject
General Medicine,Surgery
Reference27 articles.
1. Cancer statistics, 2018;Siegel;Ca - Cancer J Clin,2018
2. Palbociclib in hormone-receptor-positive advanced breast cancer;Turner;N Engl J Med,2015
3. Palbociclib and letrozole in advanced breast cancer;Finn;N Engl J Med,2016
4. NCCN clinical practice guidelines in Oncology (NCCN guidelines) breast cancer,2018
5. Ribociclib as first-line therapy for HR-positive, advanced breast cancer;Hortobagyi;N Engl J Med,2016
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation;Frontiers in Oncology;2024-07-24
2. Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer;Expert Review of Pharmacoeconomics & Outcomes Research;2024-03-20
3. CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2− Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis;Cancers;2023-06-28
4. Cost‐effectiveness of first‐line versus second‐line use of domestic anti‐PD ‐1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non‐small cell lung cancer;Cancer Medicine;2022-11-13
5. Cost-effectiveness of Ribociclib in HER2- negative breast cancer: A synthesis of current evidence;Saudi Pharmaceutical Journal;2022-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3